RT Book, Section A1 Murri, Nelda A2 Brunton, Laurence L. A2 Hilal-Dandan, Randa A2 Knollmann, Björn C. SR Print(0) ID 1164575865 T1 Goodman & Gilman Year in Review Biologics FDA Approvals T2 Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e YR 2017 FD 2017 PB McGraw-Hill Education PP New York, NY SN 9781259584732 LK accessbiomedicalscience.mhmedical.com/content.aspx?aid=1164575865 RD 2024/03/29 AB The FDA approved 33 drugs and biologics of note in 2011. Most are pharmacologically similar to others already marketed (see eTable 2). Among the remainder are 18 "first-in-class" agents for acute coronary syndrome, angioedema, chronic obstructive pulmonary disease, congenital factor XIII deficiency, depression, head lice, hepatitis C infection, lupus, lymphoma, melanoma, myelofibrosis, prostate cancer, seizures, diagnosis of Parkinsonian syndromes, and vaccination of military personnel against adenovirus (see part 1 of this series). Fourteen of the new drug approvals in 2011 were granted orphan drug status for rare diseases (see eTable 2, eTable 3, and part 1 of this series). Two of the new drugs (crizotinib for non-small cell lung cancer and vemurafenib for melanoma) were approved in conjunction with diagnostic genetic tests and represent a breakthrough in the field of personalized medicine.1 In addition, one new approval, HEMACORD is the first cord blood therapy approved in the US.2